Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Breast biopsy & localization · Washington | Breast biopsy & localization · California | |
|---|---|---|
| Surgeons, 2024 | 88 | 337 |
| Medicare fee-for-service cases | 5,486 | 21,034 |
| Growth since 2019 (Medicare FFS) | −3%/yr | +1.6%/yr |
| Forecast cases (Medicare FFS) | 5,580 in 2030 | 26,600 in 2030 |
| Forecast growth | +0.3%/yr to 2030 | +4%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 7.6 | 6.7 |
| Medicare Advantage share | 54% | 56% |
| Out of hospital | 47% (+5 pts since 2019) | 42% (+2 pts since 2019) |
| Cases per surgeon | 62 | 62 |
| Top 10 surgeons' share | 33% | 12% |
| Surgeons growing | 19 | 65 |
| New since the base year | 12 | 70 |
| Likely to stop billing it | 15 by 2026 | 50 by 2026 |
| Forecast miss, 1 year (procedure) | 3% | 3% |
| Company payments per surgeon | $422 | $2,830 |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.